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ABSTRACT
Myeloma (MM) cells and osteoclasts are mutually interacted to enhance MM 
growth while creating acidic bone lesions. Here, we explored acid sensing of MM cells 
and its role in MM cell response to acidic conditions. Acidic conditions activated the 
PI3K-Akt signaling in MM cells while upregulating the pH sensor transient receptor 
potential cation channel subfamily V member 1 (TRPV1) in a manner inhibitable 
by PI3K inhibition. The acid-activated PI3K-Akt signaling facilitated the nuclear 
localization of the transcription factor Sp1 to trigger the expression of its target 
genes, including TRPV1 and HDAC1. Consistently, histone deacetylation was enhanced 
in MM cells in acidic conditions, while repressing a wide variety of genes, including 
DR4. Indeed, acidic conditions deacetylated histone H3K9 in a DR4 gene promoter and 
curtailed DR4 expression in MM cells. However, inhibition of HDAC as well as either 
Sp1 or PI3K was able to restore DR4 expression in MM cells suppressed in acidic 
conditions. These results collectively demonstrate that acid activates the TRPV1-
PI3K-Akt-Sp1 signaling in MM cells while inducing HDAC-mediated gene repression, 
and suggest that a positive feedback loop between acid sensing and the PI3K-Akt 
signaling is formed in MM cells, leading to MM cell response to acidic bone lesions.
INTRODUCTION
Multiple myeloma (MM) has a unique propensity 
to develop and expand almost exclusively in the bone 
marrow and generates destructive bone disease. MM 
cells enhance osteoclastogenesis [1–4] while suppressing 
osteoblastogenesis [5–9], leading to devastating 
bone destruction with rapid loss of bone. Along with 
the progression of bone disease, the bone marrow 
microenvironment is skewed by MM cells, which 
underlies the unique pathophysiology of MM and confers 
aggressiveness and drug resistance in MM cells [10, 11]. 
While MM cells perturb bone metabolism to develop 
bone destruction, a crosstalk between MM cells and the 
microenvironment in bone lesions leads to a progressive 
vicious cycle phase of tumor growth and bone destruction 
[11–13].
Cancer cells, including MM cells, produce large 
amounts of protons and lactate as a consequence of 
anaerobic glycolysis (the Warburg effect) as well as low 
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O2 conditions, which leads to extracellular acidification 
(pH 6.2–6.8) in cancer lesions compared to pH 7.2–7.4 
in normal tissues [14–18]. The extracellular pH of acid-
producing osteoclasts (OCs) is generally accepted to be 
below pH 5.5 [19]. Therefore, MM-OC interactions in 
bone lesions in MM appear to create a highly acidic milieu 
due to abundant production of protons by OCs and lactate 
by proliferating glycolytic MM cells. As a result, MM 
cells need to respond to acidic tumor microenvironments 
to survive. Although tumor acidity has been shown to 
blunt the activity of immune effecter cells [16, 20–22]. 
The precise mechanisms underlying response of MM cells 
to acidic tumor conditions remain largely unknown.
Transient receptor potential cation channel 
subfamily V member 1 (TRPV1) is discovered as a 
receptor of the capsaicin and a family member of transient 
receptor potential ion channels promoting ion inflows, 
and excited by the vanilloid capsaicin, and also activated 
by noxious stimuli, including heat and extracellular 
acidification. We demonstrate herein that acidic conditions 
activate the PI3K-Akt survival signaling in MM cells 
to upregulate TRPV1 and thereby acid sensing. The 
activation of the PI3K-Akt pathway facilitated nuclear 
localization of Sp1, a transcription factor responsible 
for HDAC1 as well as TRPV1 expression in MM cells 
in acidic conditions. Consistently, histone H3 and histone 
H4 were deacetylated in MM cells in acidic conditions, 
while repressing a wide variety of genes, including DR4. 
Therefore, MM cells are suggested to sense acid more 
efficaciously in acidic conditions to activate survival 
signaling and respond to an acidic microenvironment 
created in MM bone lesions.
RESULTS
Activation of the PI3K-Akt pathway in MM cells 
by acid
A microenvironment in malignant tumors is 
generally accepted to be acidic. To clarify mechanisms 
by which MM cells survive against an acidic insult and 
respond to an acidic tumor microenvironment, we first 
measured actual pH values in MM subcutaneous tumors 
in mouse models. The average pH value was 6.86 inside 
tumors in 8 mice, while 7.35 outsides of the tumors. 
Therefore, we set pH6.8 as an acidic condition in the 
following experiments.
Because the PI3K-Akt pathway is one of the most 
important survival signaling pathways in MM cells [23, 
24, 25], we examined whether an acidic condition affects 
the PI3K-Akt signaling pathway. All MM cell lines as well 
as primary MM cells tested showed the phosphorylation 
of Akt when cultured under acidic conditions, which was 
abrogated by addition of the PI3K inhibitor LY294002 
(Figure 1A). Phosphorylation of Akt was triggered at pH 
6.8 or below but not at pH7.4. These results demonstrate 
that MM cells sense acid and activate the PI3K-Akt 
survival pathway in response to acid.
In addition, we looked at the activation of different 
signaling pathways in myeloma cells in an acidic 
condition, including PI3K-Akt, JAK-STAT3, NF-κB, 
ERK, p38MAPK and stress activated protein kinase-1 
(JNK) pathways, and found the phosphorylation of STAT3, 
p65 and JNK aside from PI3K in MM cells cultured at 
pH6.8 (Figure 1A). Therefore, Jak2/STAT3, NF-κB and 
JNK pathways appear to be also activated in MM cells in 
acidic conditions.
Acid sensing and activation of the PI3K-Akt 
pathway in MM cells via TRPV1
Extracellular pH sensors have been demonstrated 
to play an important role in sensing ambient acidity 
by tumor cells [26–29]. TRPV1 is among major pH 
sensors expressed in cancer cells [30–33], which belongs 
to an acid-sensitive ion channel. Treatment with the 
TRPV1 agonist resiniferatoxin potently induced the 
phosphorylation of Akt in MM cells, which was almost 
completely abrogated by addition of the PI3K inhibitor 
LY294002 (Figure 1B), indicating activation of the 
PI3K-Akt pathway in MM cells directly via TRPV1. 
Furthermore, the acid-induced phosphorylation of Akt 
in MM cells was mostly suppressed by addition of the 
TRPV1 antagonist SB366791 (Figure 1C), suggesting a 
predominant role of TRPV1 in acid-induced activation of 
the PI3K-Akt pathway in MM cells.
Although MM cell viability was marginally affected 
at pH6.8, MM cells underwent cell death at pH6.8 upon 
treatment with LY294002, and to a lesser extent with 
the TRPV1 antagonist SB366791 (Figure 1D). Although 
viability of the MM cells was reduced at pH6.2, LY294002 
and SB366791 still increased cell death in RPMI8226 and 
MM.1S cells. INA6 cells were mostly dead only when 
cultured at pH6.2. These results suggest the critical role 
of TRPV1 in activation of the PI3K-Akt pathway in MM 
cells and their survival in response to acid.
TRPV1 upregulation via the PI3K-Akt pathway 
in MM cells in an acidic condition
To further clarify the mechanism of acid sensing of 
MM cells, we next investigated the expression levels of 
TRPV1 in MM cells in acidic conditions. Of interest, the 
expression of TRPV1 was upregulated at protein as well as 
mRNA levels in all MM cell lines and primary MM cells 
tested at pH6.8 compared to those at pH7.4, which was 
abolished by addition of the PI3K inhibitor LY294002 as 
well as an Akt inhibitor (Figures 2A and 2B). Although 
TRPV1 was constitutively expressed in all MM cell lines 
tested and upregulated in an acidic condition, expression 
of TRPV2-5 was found to vary among the MM cells. 
These results suggest formation of positive feedback loop 
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Figure 1: The activation of the PI3K-Akt pathway in MM cells under an acidic 8 condition. A. RPMI8226, INA6, MM.1S, 
U266 MM cell lines, and primary MM cells isolated from patients with MM were cultured for 30 minutes at pH7.4 or pH6.8 with or 
without LY294002 at 10 μM as indicated (left, upper and middle). Lactic acid or sodium hydroxide was added to adjust pH of media to 
the indicated values. Cell lysates were extracted, and the protein levels of Akt and phosphorylated Akt were analyzed by Western blotting. 
RPMI8226, INA6, MM.1S MM cell lines were cultured for 30 minutes at pH7.4, pH6.8, pH6.2 or pH5.5. The protein levels of Akt and 
phosphorylated Akt were analyzed by Western blotting (left, lower). RPMI8226, INA6, MM.1S MM cell lines were cultured for 30 minutes 
at pH7.4 or pH6.8. The protein levels of PI3K, phosphorylated PI3K, STAT3, phosphorylated STAT3, p38, phosphorylated p38, p65, 
phosphorylated p65, ERK, phosphorylated ERK, JNK, and phosphorylated JNK were analyzed by Western blotting (right). β-actin was 
used as a protein loading control. B. RPMI8226, INA6, and MM.1S cells were cultured at pH7.4. The cells were treated for 30 minutes with 
the TRPV1 agonist resiniferatoxin at 1 μM or LY294002 at 10 μM alone or both in combination as indicated. The protein levels of Akt and 
phosphorylated Akt were analyzed by Western blotting. β-actin was used as a protein loading control. C. RPMI8226, INA6, and MM.1S 
cells were cultured for 30 minutes at pH7.4 or pH6.8 in the presence or absence of the TRPV1 antagonist SB366791 at 10 μM. The protein 
levels of Akt and phosphorylated Akt were analyzed by Western blotting. β-actin was used as a protein loading control. D. RPMI8226, 
INA6, and MM.1S cells were cultured in triplicate at pH7.4, pH6.8 or pH6.2 for 24 hours in the presence or absence of LY294002 at 10 
μM or SB366791 at 10 μM. Cell viability was determined by a WST-8 assay. Results are expressed as % change from the baseline with the 
mean +/- SD. *, p <0.01.
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Figure 2: Up-regulation of TRPV1 expression in MM cells under an acidic condition. RPMI8226, INA6, MM.1S, U266 MM 
cell lines as well as primary MM cells isolated from patients with MM were cultured at pH7.4 or pH6.8 with or without LY294002 at 10 
μM as indicated. Lactic acid or sodium hydroxide was added to adjust pH of media to the indicated values. A. After culturing for 24 hours, 
the protein levels of TRPV1 were analyzed by Western blotting. B. After culturing for 6 hours, TRPV1 mRNA expression was analyzed by 
RT-PCR (upper). RPMI8226, INA6, and MM.1S MM cell lines were cultured at pH7.4 or pH6.8 with or without Akt inhibitor VIII at 10 
μM as indicated. After culturing for 24 hours, the protein levels of TRPV1 were analyzed by Western blotting. After culturing for 6 hours, 
TRPV1 mRNA expression was analyzed by RT-PCR (lower, left). RPMI8226, INA6 and MM.1S MM cell lines were cultured at pH7.4 or 
pH6.8. After culturing for 6 hours, TRPV1, TRPV2, TRPV3, TRPV4, and TRPV5 mRNA expression was analyzed by RT-PCR (lower, right). 
C. RPMI8226, INA6, and MM.1S cells were cultured at pH7.4 with or without rhIGF-1 at 10 nM. LY294002 or Akt inhibitor VIII was 
added at 10 μM as indicated. After culturing for 24 hours, the protein levels of TRPV1 were analyzed by Western blotting. After culturing 
for 12 hours, TRPV1 mRNA expression was analyzed by RT-PCR. D. RPMI8226, INA6, and MM.1S cells were cultured at pH7.4 alone or 
in cocultures with osteoclasts generated from human peripheral blood monocytes as described in Materials and Methods. After culturing 
for 24 hours, the protein levels of TRPV1 were analyzed by Western blotting. After culturing for 6 hours, TRPV1 mRNA expression was 
analyzed by RT-PCR. β-actin was used as a protein loading control. GAPDH was used as an internal control.
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between acid sensing by TRPV1 and activation of the 
PI3K-Akt survival pathway.
IGF-1 activates the PI3K-Akt survival pathway as 
one of the most important survival factors for MM cells 
in the bone marrow [34, 35]. We previously reported that 
cocultures with acid-producing OCs also potently activate 
the PI3K-Akt survival pathway in MM cells [36]. To 
further confirm the role of the PI3K-Akt pathway in up-
regulation of TRPV1 expression in MM cells, we therefore 
examined the effects of IGF-1 as well as OCs. Addition 
of rh IGF-1 or cocultures with OCs enhanced TRPV1 
mRNA expression in MM cells even at pH7.4 in a manner 
inhibitable by LY294002 (Figure 2C and Figure 2D, 
respectively). The IGF-1-induced upregulation of TRPV1 
mRNA expression was further confirmed to be abolished 
by the Akt inhibitor. These results collectively demonstrate 
the critical role of the PI3K-Akt pathway in upregulation 
of TRPV1 expression in MM cells.
Acid-induced Sp1 nuclear localization and 
thereby TRPV1 upregulation in MM cells
Sp1 has been demonstrated to be a transcription 
factor responsible for TRPV1 gene expression [37, 38] 
and constitutively overexpressed in MM cells [39–41]. 
Because activation of the PI3K/Akt pathway has been 
shown to induce nuclear localization of Sp1 in other types 
of cells [42–44], we next looked at nuclear localization of 
Sp1 in MM cells. An acidic condition induced the nuclear 
localization of Sp1 in MM cells, which was suppressed 
by addition of the PI3K inhibitor LY294002 as well as 
an Akt inhibitor (Figure 3A). Further, upregulation of 
TRPV1 mRNA expression in MM cells in an acidic 
condition was suppressed by the PI3K inhibition as well 
as treatment with terameprocol, a competitive inhibitor of 
Sp1 binding to promoter regions (Figure 3B). To further 
confirm the role of Sp1, we examined the effects of Sp1 
gene knockdown on TRPV1 levels in MM cells. Treatment 
with Sp1 shRNA effectively reduced Sp1 expression at 
protein levels in RPMI8226 MM cells at both pH7.4 and 
pH6.8 (Figure 3C). TRPV1 levels were also substantially 
decreased in the MM cells with the Sp1 knockdown at 
pH6.8 as well as pH7.4. These results collectively suggest 
that an acidic condition activates the PI3K-Akt pathway 
in MM cells, which induces Sp1 nuclear localization and 
thereby TRPV1 expression to form a progressive vicious 
cycle between acid sensing and survival signaling.
Histone deacetylation and gene repression in 
MM cells under acidic conditions
Sp1 is also known as a transcription factor of 
HDAC1 gene [40, 45]. Besides TRPV1, HDAC1 
expression was upregulated in RPMI8266 cells in an acidic 
condition; Sp1 knockdown abrogated their upregulation 
of HDAC1 expression at protein as well as mRNA levels 
(Figure 3C). Therefore, we next investigated the roles of 
acidic conditions in HDAC activity in MM cells. HDAC1 
protein levels were upregulated in MM cells cultured as 
pH values were lowed in their culture media (Figure 4A). 
Conversely, acetylation of histone H3 and histone H4 was 
reduced in MM cells as ambient pH values were lowered 
(Figure 4B). The suppression of acetylation of histone H3 
and histone H4 was substantially restored upon treatment 
with the pan-HDAC inhibitor panobinostat or the HDAC 
class I-specific HDAC inhibitor valproate (Figure 4B). 
These results suggest induction of histone deacetylation 
and thereby epigenetic alteration of gene expression in 
MM cells under acidic conditions.
Because HDAC-mediated gene repression is 
suggested in MM cells under acidic conditions, we 
examined a gene expression profile of INA6 MM cells 
under acidic conditions using a cDNA microarray. 
Because INA6 MM cells expressed TRPV1 but not other 
TRPV family members, TRPV2-5 (Figure 2B), we chose 
INA6 MM cells to better understand TRPV1-mediated 
acid sensing and a gene expression profile in an acidic 
condition. Out of 30592 genes analyzed, 2037 genes were 
downregulated at pH6.8 to levels less than half of those at 
pH7.4 in INA6 cells. Treatment with the HDAC inhibitor 
valproate restored the expression of 1533 genes down-
regulated at pH6.8, including 962 cellular process-related 
genes, 810 organelle-related genes, 707 metabolic process-
related genes, 483 binding-related genes, 310 membrane-
enclosed lumen-related genes, and 93 catalytic activity-
related genes, indicating the important role of histone 
deacetylation in gene repression in MM cells under acidic 
conditions. All raw data is available on the NCBI Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE52611).
Death receptor 4 (DR4) is a cognate receptor 
for TNF-related apoptosis-inducing ligand (TRAIL) 
responsible for induction of apoptosis by TRAIL. We 
have been studied on the regulatory mechanism of DR4 
expression in MM cells to develop the strategy to enhance 
cytotoxic effects of TRAIL agonists as we previously 
reported [46]. Therefore, we are interested in the change 
of DR4 expression in MM cells in response to acid, 
and selected DR4 as a representative gene from many 
differentially expressed genes in the gene expression 
profile in an acidic condition. According to the above 
gene expression profile in INA6 MM cells, a DR4 gene 
was confirmed to be clearly repressed in MM cells under 
an acidic condition in an HDAC-dependent manner. 
DR4 protein levels were also found to be decreased in 
RPMI8226, INA6, and MM.1S cells cultured for 24 hours 
at acidic conditions in a pH-dependent manner (Figure 
4C). Further, DR4 mRNA expression and surface levels 
of DR4 were also decreased at pH6.8 (Figures 4D and 
Figure 4E, respectively). Therefore, DR4 is regarded as 
a representative gene repressed in MM cells in acidic 
conditions.
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DR4 expression was suppressed in MM cells 
under acidic conditions in an HDAC-dependent 
manner
We next investigated the precise mechanism of 
epigenetic regulation of gene expression in MM cells 
under acidic conditions, using DR4 as a representative 
gene repressed in an acidic condition in an HDAC-
dependent manner. To further confirm DR4 gene 
repression by histone deacetylation, we analyzed the 
acetylation status of histone H3K9 in a DR4 promoter by a 
ChIP assay because deacetylation of the promoter region is 
known to suppress DR4 gene expression. The acetylation 
of histone H3K9 in a DR4 promoter was markedly reduced 
in MM cells under acidic conditions in a pH-dependent 
manner (Figure 5A).
Figure 3: Acid-induced Sp1 nuclear localization and TRPV1 up-regulation in MM cells. A. RPMI8226, INA6, and MM.1S 
cells were cultured for 24 hours at pH7.4 or pH6.8 with or without LY294002 or Akt inhibitor VIII at 10 μM. The nuclear and cytoplasmic 
extracts of MM cells were harvested, and the protein levels of Sp1 were analyzed by Western blotting. The nuclear protein p84 was used 
as a protein loading control. B. RPMI8226, INA6, and MM.1S cells were cultured for 6 hours at pH7.4 or pH6.8. LY294002 and the Sp1 
inhibitor terameprocol (TMP) were added at 10 μM and 50 μM, respectively, as indicated. TRPV1 mRNA expression was analyzed by RT-
PCR. GAPDH was used as an internal control. C. RPMI8226 cells were transfected with human Sp1 shRNA or control shRNA as described 
in Materials and Methods. These cells were cultured at pH7.4 or pH6.8. After culturing 24 and 6 hours, cell lysates and total RNA were 
collected. The expression of Sp1, TRPV1, and HDAC1 were analyzed by Western blotting (left) and RT-PCR (right). β-actin and GAPDH 
were used as a protein loading control and an internal control, respectively.
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Figure 4: Histone acetylation and DR4 repression in MM cells under acidic conditions. A. RPMI8226, INA6, and MM.1S 
cells were cultured for 24 hours at the indicated pH values. HDAC1 protein levels were analyzed by Western blotting. B. The cells were 
cultured for 24 hours at the indicated pH values in the presence or absence of the HDAC inhibitor panobinostat at 10 nM or valproate (VPA) 
at 100 μg/mL. The protein levels of acetylated histone H3 and histone H4 were analyzed by Western blotting. Histone H3 and β-actin were 
used as protein loading controls. C. RPMI8226, INA6, and MM.1S cells were cultured for 24 hours at the indicated pH values. The protein 
levels of DR4 were analyzed by Western blotting. β-actin was used as a protein loading control. D. The cells were cultured for 6 hours at 
pH7.4 or pH6.8. DR4 mRNA expression was analyzed by RT-PCR. GAPDH was used as an internal control. E. RPMI8226, INA6, MM.1S, 
and U266, as well as primary MM cells were cultured for 24 hours at pH7.4 or pH 6.8. The surface expression of DR4 was analyzed by flow 
cytometry. Solid and dotted lines show the expression levels of DR4 of the cells cultured at pH7.4 and pH6.8, respectively. Background 
staining with control IgG was shown in gray.
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Figure 5: Restoration of DR4 expression in MM cells by HDAC inhibition under acidic conditions. A. RPMI8226, INA6, 
and MM.1S cells were cultured at the indicated pH values for 6 hours. The acetylation of H3K9 was analyzed by the ChIP assay with the 
anti-acetylated H3K9 antibody as described in the Materials and Methods. Immunoprecipitated and total input DNA fractions were subject 
to analysis for the DR4 promoter by RT-PCR. B. RPMI8226, INA6, and MM.1S cells were cultured at pH7.4 or pH6.8 in the presence 
or absence of valproate (VPA) at 100 μg/mL or panobinostat at 10 nM. After culturing 24 and 6 hours, cell lysates and total RNA were 
collected, respectively. The Expression of DR4 were analyzed by Western blotting (upper) and RT-PCR (lower). β-actin and GAPDH were 
used as a protein loading control and an internal control, respectively. C. RPMI8226, INA6, and MM.1S cells were cultured for 24 hours 
at pH7.4 or pH6.8 with or without 5-azacitizine (5-aza) at 2.5 μM. Protein levels of DR4 were analyzed by Western blotting. β-actin was 
used as a protein loading control. D. RPMI8226, INA6, and MM.1S cells were cultured for 24 hours at pH7.4 or pH6.8 with or without the 
anti-DR4 agonistic antibody R1-B12 (B12) at 20 μg/mL. Valproate (VPA) at 100 μg/mL or panobinostat at 10 nM was added as indicated. 
Cell viability was determined by the WST-8 assay. White and black bars represented the condition of pH7.4 and pH6.8, respectively. Results 
are expressed as % change from the baseline with the mean +/- SD. *, P <0.01.
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Treatment with the HDAC inhibitors valproate as 
well as panobinostat restored DR4 expression suppressed 
at pH6.8 at protein and mRNA levels in RPMI8226, INA6, 
and MM.1S cells, whereas valproate and panobinostat 
marginally affected DR4 expression in these cells at 
pH7.4 (Figure 5B). However, treatment with the DNA 
methylation inhibitor 5-azacitidine showed only marginal 
effects (Figure 5C). Cross-linking of DR4 with the anti-
DR4 agonistic antibody R1-B12 potently induced death 
in DR4-expressing RPMI8226, INA6, and MM.1S cells 
at pH7.4; however, the cytotoxic effects of R1-B12 were 
blunted at pH6.8 (Figure 5D). Because the cytotoxic 
effects of the anti-DR4 agonistic antibody largely depend 
on the surface levels of DR4 [46–48], the attenuation of 
R1-B12-induced MM cell death at pH6.8 appeared to be 
due to the down-regulation of DR4 expression in MM 
cells. However, HDAC inhibition by valproate as well 
as panobinostat restored the anti-MM effects of R1-B12 
under acidic conditions (Figure 5D). These results suggest 
the HDAC-mediated repression of DR4 gene in MM cells 
in an acidic environment blunts the efficacy of DR4-
mediated immunotherapy against MM cells, which can be 
restored by HDAC inhibition.
Inhibition of PI3K-Akt-Sp1 pathway restored 
DR4 expression down-regulated in MM cells in 
an acidic condition
Because HDAC1 is a target gene of Sp1, and 
because the PI3K-Akt-Sp1 pathway was activated 
in MM cells in acidic conditions (Figure 3), we next 
investigated the role of the PI3K-Akt-Sp1 pathway in DR4 
repression in MM cells in acidic conditions. Blockade of 
transcriptional activity of Sp1 by terameprocol as well 
as Sp1 gene knockdown with Sp1 shRNA were able to 
substantially suppress HDAC1 expression in MM cells at 
pH7.4 and abolish upregulation of its expression at pH6.8 
(Figures 3C and 6A). In addition, treatment with the Sp1 
inhibitor terameprocol restored DR4 expression in MM 
cells suppressed at pH6.8 (Figure 6B). Consistent with 
the observation that the nuclear localization of Sp1 was 
enhanced through activation of the PI3K-Akt pathway in 
MM cells under acidic conditions (Figure 3A), the PI3K 
inhibitor LY294002 restored DR4 expression in MM cells 
suppressed at pH6.8 at protein as well as mRNA levels 
(Figure 6C), suggesting that DR4 repression in MM cells 
under acidic conditions is largely mediated by activation 
of the PI3K-Akt-Sp1 pathway. Because DR4 repression 
was ameliorated by HDAC inhibition in MM cells under 
acidic conditions (Figure 5B), these results suggest that 
acidic conditions activate the PI3K-Akt-Sp1-HDAC1 
pathway to cause HDAC-mediated DR4 repression in MM 
cells.
We finally looked at the expression of DR4 and the 
pH sensor TRPV1 in MM tumors in mouse models with 
subcutaneous inoculation of RPMI8226 cells. The average 
pH value was found to be 6.86 inside tumors. DR4 protein 
levels were decreased in the in vivo tumors compared 
with RPMI8226 cells cultured at pH7.4, whereas TRPV1 
was upregulated in these tumors (Figure 6D). Therefore, 
MM cells may enhance acid sensing while reducing DR4 
expression to mitigate DR4-mediated apoptotic insults in 
acidic tumorous lesions in vivo.
DISCUSSION
Cancer cells acidify their surrounding milieu while 
they grow; extracellular pH values have been reported 
to be 6.2–6.8 in cancer lesions compared to pH 7.2–7.4 
in normal tissues [14–18]. As expected, we found the 
actual pH values were around 6.8 inside subcutaneous 
MM tumors in mouse models. MM cells stimulate OC 
formation and activation in the bone marrow; OCs 
produce a large amount of protons to form resorption pits 
in which pH values are generally accepted to be below 
5.5 [19]. Therefore, MM bone lesions appear to serve an 
acidic milieu to MM cells where MM cells preferentially 
reside and grow. We expected pH values in acidic bone 
lesions in patients with MM are similar to those observed 
in subcutaneous MM tumors in mouse models (around 
6.8) or more acidic at least in close vicinity to OCs in 
MM bone lesions, although there has been no information 
about actual pH values in bone lesions in patients with 
MM because of difficulty in measuring actual pH values 
in the bone marrow. Therefore, we looked at the effects of 
pH 6.8 as a representative pH value in MM tumors in the 
present study.
Because TRPV1 is among major pH sensors 
expressed in cancer cells [30–33], we first examined the 
effects of an antagonist and agonist of TRPV1 and found 
the critical role of TRPV1 in acid-induced activation of 
the PI3K/Akt pathway in MM cells (Figure 1B and 1C). 
Therefore, we focused on TRPV1 in MM cells. The 
present study demonstrates that the PI3K-Akt pathway 
is activated in MM cells under acidic conditions, which 
further upregulates the expression of TRPV1 to facilitate 
acid sensing, thereby forming a positive feedback loop 
between acid sensing and activation of the PI3K-Akt 
survival signaling. The activation of the PI3K-Akt 
pathway in MM cells in acidic conditions facilitated 
the nuclear localization of the transcription factor Sp1 
responsible for TRPV1 gene expression, which appears 
to be one of the mechanisms of the acid-induced 
upregulation of TRPV1 in MM cells. Therefore, MM cells 
are suggested to activate the PI3K-Akt survival pathway in 
response to acid to adapt to and survive in a harsh acidic 
tumor microenvironment.
We also found that histone H3 and histone H4 were 
deacetylated in MM cells in acidic conditions, while 
repressing a wide variety of genes. This was partly due to 
upregulation of HDAC1 expression in MM cells through 
the acid-induced nuclear localization of Sp1, which also 
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Figure 6: Restoration of DR4 expression in MM cells by inhibition of PI3K-Akt-Sp1 pathway under acidic conditions. 
RPMI8226, INA6, and MM.1S cells were cultured for 6 hours at pH7.4 or pH6.8 in the presence or absence of terameprocol (TMP) at 
50mM. A. After culturing for 24 hours, the protein levels of HDAC1 were analyzed by Western blotting. β-actin was used as a protein 
loading control. After culturing for 6 hours, HDAC1 mRNA expression was analyzed by RT-PCR. GAPDH was used as an internal control. 
B. After culturing for 24 hours, DR4 protein levels were analyzed by Western blotting. β-actin was used as a protein loading control. After 
culturing for 6 hours, DR4 mRNA expression was analyzed by RT-PCR. GAPDH was used as an internal control. C. The cells were cultured 
at pH7.4 or pH6.8 in the presence or absence of LY294002 at 10μM. After culturing 24 and 6 hours, cell lysates and total RNA were 
collected, respectively. The expression of DR4 were analyzed by Western blotting (upper) and RT-PCR (lower). β-actin and GAPDH were 
used as a protein loading control and an internal control, respectively. D. The protein levels of DR4 and TRPV1 were analyzed by Western 
blotting in RPMI8226 cells cultured at pH7.4 and subcutaneous tumors of RPMI8226 cells in 3 mouse MM models.
Oncotarget70457www.impactjournals.com/oncotarget
acts as a transcription factor for HDAC1gene. Indeed, 
valproate, a HDAC inhibitor rather specific to class1 
HDACs including HDAC1, restored the expression of 
substantial numbers of genes which were suppressed 
in INA6 MM cells at pH6.8, suggesting a significant 
contribution of gene repression in MM cells in acidic 
conditions by class1 HDACs.
DR4 was found to be one of such genes repressed 
in a HDAC-dependent manner in an acidic condition. 
We further dissected the mechanism of HDAC-mediated 
gene repression in MM cells in acidic conditions, using 
DR4. DR4 expression was curtailed (Figures 4C, 4D 
and 4E), and histone H3K9 in a DR4 gene promoter was 
deacetylated in MM cells (Figure 5A) in acidic conditions. 
However, inhibition of HDAC as well as Sp1 or PI3K was 
able to restore their DR4 expression curtailed in acidic 
conditions (Figures 5B, 6B and 6C). Such acid-induced 
reduction of DR4 expression protects MM cells from DR4 
agonist-induced cell death (Figures 5D), which may limit 
DR4 agonist-based immunotherapy against MM cells. 
Inhibition of HDAC activity as well as Sp1 is suggested to 
be able to restore MM cell susceptibility to DR4 agonists 
in acidic conditions in MM bone lesions.
In addition to HDAC-mediated gene repression, 
a number of genes were upregulated in MM cells under 
an acidic condition. Because Sp1 transcriptionally 
upregulates various important genes, the roles of Sp1 in 
acid-induced alteration of gene expression in MM cells 
should be further clarified to better understand MM 
cell biology in acidic conditions, which may lead to 
development of new therapeutic options against MM.
The present study also cautions that we should 
take into account alteration of gene expression in cancer 
cells when analyzed in non-acidic culture conditions, 
which may cause misinterpretation of genetic profiles in 
cancer cells in vivo. We need to establish sophisticated 
experimental conditions to correctly reflect ambient tumor 
microenvironment and further clarify precise regulation 
of gene expression in cancer cells in pathological 
microenvironments surrounding them.
Based on the present study, Akt inhibitors may be 
able to target MM cells in acidic conditions; and HDAC 
inhibitors may resume the expression of various genes 
in MM cells in acidic conditions, which may sensitize 
MM cells to therapeutic agents, including an anti-DR4 
agonistic antibody. Therefore, combinatory treatment 
with Akt inhibitors or HDAC inhibitors can be envisioned 
to improve the therapeutic efficacy of anti-MM agents 
against MM cells in acidic conditions.
MATERIALS AND METHODS
Reagents
The following reagents were purchased from the 
indicated manufacturers: rabbit polyclonal anti-human 
DR4 antibody, anti-human TRPV1 antibody, and anti-
human HDAC1 antibody from Abcam (Cambridge, UK); 
mouse polyclonal anti-β-actin antibody and valproate from 
Sigma (St. Louis, MO); rabbit polyclonal anti-Histone H3 
antibody, rabbit polyclonal anti-acetyl-histone H3 antibody 
and anti-acetyl-histone H4 antibody from Merck Millipore 
(Billerica, MA); rabbit polyclonal anti-Sp1 antibody, anti-
Akt antibody, anti-phosphorylated Akt antibody, anti-PI3K 
antibody, anti-phosphorylated PI3K antibody, anti-STAT3 
antibody, anti-phosphorylated STAT3 antibody, anti-p38 
antibody, anti-phosphorylated p38 antibody, anti-p65 
antibody, anti-phosphorylated p65 antibody, anti-ERK 
antibody, anti-phosphorylated ERK antibody, anti-JNK 
antibody, anti-phosphorylated JNK antibody, horseradish 
peroxidase (HRP)-anti-rabbit IgG and anti mouse IgG 
from Cell Signaling Technology (Beverly, MA); rh IGF-
1 from R&D Systems (Minneapolis, MN); panobinostat 
from Cayman Chemical Company (Ann Arbor, MI); and 
5-azacytidine and Akt inhibitor VIII from Calbiochem 
(Darmstadt, Germany). The human monoclonal anti-DR4 
agonistic IgG antibody R1-B12 was kindly provided by 
Kyowa Hakko Kirin Co. Ltd. (Tokyo, Japan).
Cells and cultures
Human MM cell lines, RPMI8226 and U266 
were obtained from American Type Culture Collection 
(ATCC) (Rockville, MD). The MM cell lines INA6, 
MM.1S, were kindly provided by Dr. Renate Burger 
(University of Kiel, Kiel, Germany) and Dr.Steven Rosen 
(Northwestern University, Chicago, IL), respectively. 
At the beginning of this study, all the 4 cell lines were 
authenticated by the surface expression of CD38 and 
CD138 by flow cytometry and cellular morphology. 
MM cells were purified from bone marrow mononuclear 
cells from patients with MM by positive selection using 
CD138 microbeads and Miltenyi magnetic cell sorting 
system (Miltenyi Biotec, Auburn, CA) according to the 
manufacture's instruction. MM cells were cultured in 
RPMI1640 supplemented with 5% fetal bovine serum, 
2 mM of L-glutamine (Sigma), 100 U/mL of penicillin 
G and 100 mg/mL of streptomycin (Sigma). The levels 
of pH in culture media were adjusted by adding lactic 
acid (Wako, Osaka, Japan) or sodium hydroxide (Wako). 
OCs were generated from peripheral blood mononuclear 
cells as previously reported.13 All procedures involving 
human specimens were performed with written informed 
consent according to the Declaration of Helsinki and 
using a protocol approved by the Institutional Review 
Board for human protection.
Flow cytometry
Cell preparation and staining in flow cytometry 
were performed as described previously [13]. Briefly, 
approximately 106 cells were incubated in 100 μL PBS 
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with 2% human γ-globulin (Japan Blood Products 
Organization, Tokyo, Japan) with FITC-conjugated 
monoclonal antibodies on ice for 40 minutes, and 
then washed. Samples were analyzed by flow 
cytometry using EPICS-Profile (Coulter Electronics, 
Hialeah, FL).
Western blot analysis
Whole cell lysate was lysed in RIPA buffer, and 
nuclear extract was lysed by NE-PER nuclear and 
cytoplasmic extraction reagent kit (Thermo Fisher 
Scientific, Rockford, IL, USA). These lysates were 
supplemented with 1 mM phenylmethylsulfonyl fluoride 
and protease inhibitor cocktail solution (Sigma). Cell 
lysates and conditioned media were electrophoresed in 
10% SDS-PAGE gel and blotted onto polyvinylidene 
difluoride membranes (Millipore, Bedford, MA). After 
blocking with 5% non-fat dry milk, the membranes 
were incubated with primary antibodies overnight 
at 4°C, followed by washing and addition of a 
horseradish-conjugated secondary antibody for 1 hour. 
The protein bands were visualized with an Enhanced 
Chemiluminescence Plus Western Blotting Detection 
System (Amersham Biosciences, Piscataway, NJ).
RT-PCR
Total RNA was extracted from cells using 
TRIZOL reagent (Gibco BRL, Rockville, MD). For 
reverse transcription-polymerase chain reaction (RT-
PCR), 2 μg total RNA was reverse-transcribed with 
Superscript II (Gibco) in a 20μL reaction solution. 
One tenth of the RT-PCR products were used for 
subsequent PCR analysis with 24–30 cycles of 95°C 
for 30 seconds, 58°C for 30 seconds, and 72°C for 30 
seconds. The following primers were used: DR4 forward, 
5'-TGGCACACAGCAATGGGAACATAG-3', DR4 
reverse, 5'-GAAACACACCCTGTCCATGCACTT-3', 
DR4 promoter forward, 5'-AGCGCAATGGCT 
CCATCTCGGCTC-3', DR4 promoter reverse, 
5'-AGTCACGGTCCTGCCTGCGAAGAA-3', HDAC1 
forward, 5'-AACCTGCCTATGCTGATGCTGG-3', HDAC1 
reverse, 5'-TCGTCTTCGTCCTCATCG-3', TRPV1 
forward, 5'-AACTGGACCACCTGGAACAC-3', TRPV1 
reverse 5'-GCCTGAAACTCTGCTTGACC-3', TRPV2 
forward, 5'-GTGACGGAACAGCCCACGGT-3', TRPV2 
reverse 5'-CAGTGATGCCTGGCCCTGATGG-3', TRPV3 
forward, 5'-GCTGAAGAAGCGCATCTTTGCA-3', TRPV3 
reverse 5'-TCATAGGCCTCCTCTGTGTACT-3', TRPV4 
forward, 5'-CCCGTGAGAACACCAAGTTT-3', TRPV4 
reverse 5'-TCACTCCAGGGCATTTCTTC-3', TRPV5 
forward 5'-TGATGGGTGACACACACTGG-3', TRPV5 
reverse 5'-GAAGCACTCGCAAAGGATTT-3', GAPDH 
forward, 5'-AATCCCATCACCATCTTCCA-3’, GAPDH 
reverse, 5'-TGGACTCCACGACGTACTCA-3'.
ChIP assay
ChIP assay was performed using a ChIP assay kit 
(Millipore). Cells were treated with 1% formaldehyde 
for 10 minutes at 37 °C. The lysates were sonicated 5 
times with each time for 30 seconds, and centrifuged. 
The supernatants were diluted in a ChIP dilution buffer, 
and incubated overnight at 4 °C with anti-acetyl-H3K9 
antibody. Then, 60 μL of salmon sperm DNA/protein A 
agarose beads-50% slurry was added, and incubated for 2 
hours at 4 °C with rotation. After the incubation, the beads 
were pelleted, and washed with low and high salt buffers, 
and finally three times with LiCl buffer. The immune 
complexes were incubated for 4 hours at 65 °C with 500 
μL of fresh elution buffer (1% SDS, 0.1 M NaHCO3) and 
20 μL of 5 M NaCl, and eluted, followed by the addition 
of 2 μL of 500 mM EDTA, 1 μL of 1 M Tris and 1 μL 
of proteinase K. The DNA solution was extracted with 
a phenol/chloroform/isoamyl alcohol mixture to remove 
protein contaminants, and precipitated with 100% ethanol. 
After the precipitation step, pellets were washed with 70% 
ethanol, and dissolved in 20 μL distilled water.
Cytotoxicity assay
In cytotoxic analyses with R1-B12, R1-B12 was 
added into cultures, followed by cross-linking with goat 
F(ab′)2 anti-human IgG Fc. After culturing for 24 hours, 
cell viability was determined by Cell Counting Kit-8 
assay (DOJINDO, Kumamoto, Japan) according to the 
manufacturer’s instructions. Briefly, cells were incubated 
in culture plates with 2-(2-methoxy-4-nitrophenyl)-3-
(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium 
monosodium salt (WST-8) for 4 hours. The absorbance 
of each well was measured at 450 nm with a microtiter 
plate reader (Model 450 micro plate reader; Bio-Rad 
Laboratories, Hercules, CA).
cDNA microarray
INA6 cells were cultured for 12 hours, at pH7.4 
or pH6.8 in the absence or presence of valproate at 100 
μg/mL. The total RNA was isolated using RNeasy Mini 
kit (Qiagen, Valencia, CA, USA). Cyanine-3 (Cy3) 
labeled cRNA was prepared from 0.13 μg RNA using 
the One-Color Low Input Quick Amp Labeling kit 
(Agilent Technologies, Santa Clara, CA) according to 
the manufacturer's instructions, followed by RNeasy 
column purification (Qiagen). Dye incorporation and 
cRNA yield were checked with the NanoDrop ND-
1000 Spectrophotometer. 1.65 μg of Cy3-labelled 
cRNA (specific activity >13.0 pmol Cy3/μg cRNA) was 
fragmented at 60°C for 30 minutes in a reaction volume 
of 55 μL containing 1x Agilent fragmentation buffer and 
2x Agilent blocking agent following the manufacturers 
instructions. On completion of the fragmentation reaction, 
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55 μL of 2x Agilent hybridization buffer was added to the 
fragmentation mixture and hybridized to Agilent Whole 
Human Genome Oligo Microarrays (G4845A) for 17 
hours at 65°C in a rotating Agilent hybridization oven. 
After hybridization, microarrays were washed 1 minute 
at room temperature with GE wash buffer 1 (Agilent) 
and 1 minute with 37Â°C GE wash buffer 2 (Agilent), 
then dried immediately by brief centrifugation. Slides 
were scanned immediately after washing on the Agilent 
DNA Microarray Scanner (G2505C) using one color scan 
setting for 4x44k array slides (Scan Area 61x21.6 mm, 
Scan resolution 5um, Dye channel is set to Green). The 
scanned images were analyzed with Feature Extraction 
Software 10.7 (Agilent) using default parameters (protocol 
GE1-107_Sep09 and Grid: 026652_D_F_20110325) to 
obtain a background subtracted and spatially detrended 
Processed Signal intensities. Features flagged in Feature 
Extraction as Feature Non-uniform outliers were excluded. 
All raw data is available on the NCBI Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE52611).
Short-hairpin RNA (shRNA) transduction
shRNA lentiviral transduction particles (Sigma-
Aldrich) were used and shRNA transduction was 
performed with the MagnetoFection-ViroMag R/L (OZ 
Biosciences, Marseille, France) as previously described. 
Sp1 shRNA (NM_138473.2-5s21c1) (Sigma-Aldrich) 
or control shRNA (Sigma-Aldrich) were designed by 
MISSION®. To increase the transduction efficiency, 1 mL 
of RPMI8226 cell suspension (105 cells) was mixed with 
20 μL CombiMag® (OZ Biosciences) and incubated for 15 
minutes. Then, the cells were distributed to 96-well plates 
(100 μL/well) and placed for 15 minutes on a magnetic 
plate. To prepare lentiviral transduction particles, 1 
multiplicity of infection (MOI) of lentiviral particles were 
added to 2 μL of ViroMag R/L beads (OZ Biosciences), 
and incubated for 15 minutes at room temperature. Then 
the virus particles/ViroMag R/L were added to each well, 
and the cells were incubated on the magnet plate for 60 
minutes at room temperature. The culture plates were 
removed from the magnetic plate and the cells were 
cultured at 37°C with 5% CO2 for 24 hours. To establish 
stable Sp1 knockdown cells, clones were selected by 
treatment with puromycin (Sigma) at 5 μg/mL.
Mouse MM model
RPMI8226 cells (5x106 cells/mouse) were 
subcutaneously inoculated to SCID mice pretreated 
with anti-asyaloGM1 antibody (Wako, Osaka, Japan), 
as previously described [49, 50]. After enlarging 
subcutaneous tumors more than 2 cm in diameter, we 
inserted pH sensors (InLab, Mettler Toled, Columbus, 
OH) directly into tumors or subcutaneous regions outside 
tumors and measured pH values. After measuring pH, 
tumors were resected to prepare cell lysates.
Statistical analysis
Statistical significance was determined by one-way 
analysis of variance (ANOVA) with Scheffe's post hoc 
tests. The minimal level of significance was P=0.05.
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